Companies prefer non-transferable CVRs because publicly traded transferable CVRs require regulatory work and incur higher costs Imagine a scenario in which the re-taking company doesn`t want to pay much, if any, for a drug (or other product) that may not work, has a limited market, or requires significant investment. On the other hand, the acquired company wants to obtain the full value of its assets and show shareholders that it has maximum value for them. If, under this CVR Convention, a person may submit, issue or execute two requests, requests, consents, certificates, declarations, notices or any other instrument under this CVR Convention, it shall be consolidated and constitute an instrument. This CVR Agreement shall be signed in any number of equivalents having the same effect as if the signatures of each counterparty were on a single instrument, and all such equivalents shall be considered together as originals of this CVR Agreement. . . .